Get the latest news and updates
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
Confirmed Presenting Companies:
Dr. Lou is a Program Director in the Small Business Innovation Research Development Center at the National Cancer Institute. She manages SBIR & STTR awards, as well as actively engages in developing targeted solicitations, guiding small businesses to develop applications and facilitating interaction between awardees and potential investors and partners. Dr. Lou has over 15 years experience in research and product development for diagnosis and drug development. Prior to joining NCI she held a variety of scientific and management positions in pharmaceutical and biotech companies, including Johnson & Johnson, LumiCyte, Applied Biosystems (now part of Thermo Fisher Scientific corporation) and diaDexus. Dr. Lou received her PhD degree in Molecular & Cellular Pharmacology from University of Miami and completed her postdoctoral training at Stanford University.
Jeremy Norris is a Co-Founder and CEO of Frontier Diagnostics, a clinical diagnostics company developing next-generation molecular assays for tissue pathology. Frontier Diagnostics proprietary diagnostic platform utilizes mass spectrometry to measure protein signature from tissue sections, while maintaining spatial registration with anatomical features. Dr. Norris has worked in both academic and industry with an emphasis in mass spectrometry and separation science. His work has resulted in the successful launch of numerous commercial products and services. Dr. Norris obtained a Ph.D. in Chemistry from Vanderbilt University where he is currently Associate Professor of Biochemistry & Chemistry and Managing Director of the Mass Spectrometry Research Center.
Clinical Dx Showcase: Frontier Diagnostics, LLC
Frontier Diagnostics, LLC was founded to discover, develop, and commercialize innovative tissue-based diagnostics that improve patient care.
MelanoMap: Molecular Diagnosis Of Ambiguous Skin Lesions
MelanoMap is a protein based, molecular diagnostic developed on a novel Imaging Mass Spectrometry platform, a technology that combines the spatial information of microscopy with the unparalleled molecular specificity and sensitivity of mass spectrometry.
Mr. Richardson’s company is focused on preventing trial-and-error cancer treatments by using predictive analytics to recommend treatment regimens that avoid drug resistance. His team has developed technology for mapping tumors that creates spatial (in-situ) and multi-omic data to form comprehensive, network-level understanding of tumors. Richardson’s team started development of the technology in 2016 and has since optimized its use for clinical patient samples and demonstrated novel screening methods in breast cancer patients with industry partners. Mr. Richardson and his team have received multiple awards and recognitions for their work, including the Flinn Foundation’s Bioscience Entrepreneurship Award, an Arizona Bioscience Award for Rapid Commercialization, Best Oncology-Focused Precision Medicine Company, and named one of Arizona’s Top 12 to Watch in Business for 2019. They have also won several National Science Foundation and National Cancer Institute grants to continue development of their technology.
Clinical Dx Showcase: bioSyntagma
Data-driven biotech company addressing cancer drug resistance through novel tissue analysis and predictive analytics.
Tackling Drug Resistance: Spatial Mapping And AI
Drug resistance and patient stratification are critical obstacles to personalized medicine. bioSyntagma presents a platform for mapping patient tumors (spatial + multi-omic) paired with Artificial Intelligence for interpreting system-level environmental biomarkers to predict response and recommend combination treatments.